BHC Quote, Financials, Valuation and Earnings

Edesa Biotech, Inc. has a net margin of 6.75% compared to Bausch Health Cos., Inc.'s net margin of --. Bausch Health Cos., Inc.'s return on equity of -- beat Edesa Biotech, Inc.'s return on equity of -77.48%.

Bausch Health Cos., Inc. has a consensus price target of $7.29, signalling upside risk potential of 1.47%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 746.15%. Given that Edesa Biotech, Inc. has higher upside potential than Bausch Health Cos., Inc., analysts believe Edesa Biotech, Inc. is more attractive than Bausch Health Cos., Inc..

Bausch Health Cos., Inc. has a beta of 0.407, which suggesting that the stock is 59.309% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.

Bausch Health Cos., Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch Health Cos., Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.

Bausch Health Cos., Inc. quarterly revenues are $2.7B, which are larger than Edesa Biotech, Inc. quarterly revenues of --. Bausch Health Cos., Inc.'s net income of $181M is higher than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Bausch Health Cos., Inc.'s price-to-earnings ratio is 7.41x while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch Health Cos., Inc. is 0.27x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience Corp. has a net margin of 6.75% compared to Bausch Health Cos., Inc.'s net margin of -2178.51%. Bausch Health Cos., Inc.'s return on equity of -- beat Lexaria Bioscience Corp.'s return on equity of -147.19%.

Bausch Health Cos., Inc. has a consensus price target of $7.29, signalling upside risk potential of 1.47%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $5.33 which suggests that it could grow by 852.38%. Given that Lexaria Bioscience Corp. has higher upside potential than Bausch Health Cos., Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Bausch Health Cos., Inc..

Bausch Health Cos., Inc. has a beta of 0.407, which suggesting that the stock is 59.309% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.

Bausch Health Cos., Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch Health Cos., Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.

Bausch Health Cos., Inc. quarterly revenues are $2.7B, which are larger than Lexaria Bioscience Corp. quarterly revenues of $174K. Bausch Health Cos., Inc.'s net income of $181M is higher than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, Bausch Health Cos., Inc.'s price-to-earnings ratio is 7.41x while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch Health Cos., Inc. is 0.27x versus 14.29x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of 6.75% compared to Bausch Health Cos., Inc.'s net margin of --. Bausch Health Cos., Inc.'s return on equity of -- beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Bausch Health Cos., Inc. has a consensus price target of $7.29, signalling upside risk potential of 1.47%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 472.27%. Given that Oncolytics Biotech, Inc. has higher upside potential than Bausch Health Cos., Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Bausch Health Cos., Inc..

Bausch Health Cos., Inc. has a beta of 0.407, which suggesting that the stock is 59.309% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

Bausch Health Cos., Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch Health Cos., Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Bausch Health Cos., Inc. quarterly revenues are $2.7B, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. Bausch Health Cos., Inc.'s net income of $181M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Bausch Health Cos., Inc.'s price-to-earnings ratio is 7.41x while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch Health Cos., Inc. is 0.27x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals, Inc. has a net margin of 6.75% compared to Bausch Health Cos., Inc.'s net margin of -867.29%. Bausch Health Cos., Inc.'s return on equity of -- beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.

Bausch Health Cos., Inc. has a consensus price target of $7.29, signalling upside risk potential of 1.47%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.40 which suggests that it could grow by 23.09%. Given that Xenon Pharmaceuticals, Inc. has higher upside potential than Bausch Health Cos., Inc., analysts believe Xenon Pharmaceuticals, Inc. is more attractive than Bausch Health Cos., Inc..

Bausch Health Cos., Inc. has a beta of 0.407, which suggesting that the stock is 59.309% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.689%.

Bausch Health Cos., Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bausch Health Cos., Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Bausch Health Cos., Inc. quarterly revenues are $2.7B, which are larger than Xenon Pharmaceuticals, Inc. quarterly revenues of --. Bausch Health Cos., Inc.'s net income of $181M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, Bausch Health Cos., Inc.'s price-to-earnings ratio is 7.41x while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bausch Health Cos., Inc. is 0.27x versus 473.02x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.